Company / Capital Expenditures
Caribou Biosciences, Inc. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.4M
FY2025
5-year range
$884.0K / $11.6M
FY2021-FY2025
Trend
-88.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $6M to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 3-year CAGR of -13.8%.
Declined from $6M to $1M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -13.8%, indicating a declining trend.
- In FY2025, capital expenditures decreased 88.3% year-over-year.
- Peak capital expenditures was recorded in FY2024.
- Lowest capital expenditures in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | -88.3% |
| FY2024 | $11.6M | +79.9% |
| FY2023 | $6.5M | +204.3% |
| FY2022 | $2.1M | +139.9% |
| FY2021 | $884.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026